Cargando…
Rivastigmine as a Symptomatic Treatment for Apathy in Parkinson's Dementia Complex: New Aspects for This Riddle
Over 90% of PDD patients show at least one neuropsychiatric symptom (NPS); in the 60–70% two or more NPS are present. Their incidence is important in terms of prognosis and severity of pathology. However, among all NPS, apathy is often the most disturbing, associated with greater caregiver's bu...
Autores principales: | Moretti, Rita, Caruso, Paola, Dal Ben, Matteo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376458/ https://www.ncbi.nlm.nih.gov/pubmed/28409049 http://dx.doi.org/10.1155/2017/6219851 |
Ejemplares similares
-
Apathy in Parkinson's Disease: An Electrophysiological Study
por: Mathis, Stéphane, et al.
Publicado: (2014) -
Rivastigmine for the treatment of dementia associated with Parkinson’s disease
por: Reingold, Jennifer L, et al.
Publicado: (2007) -
Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson’s Disease Dementia
por: Oh, Yoon-Sang, et al.
Publicado: (2015) -
Vitamin D, Homocysteine, and Folate in Subcortical Vascular Dementia and Alzheimer Dementia
por: Moretti, Rita, et al.
Publicado: (2017) -
The perception of apathy by caregivers of patients with dementia in
Parkinson's disease
por: Camargo, Carlos Henrique Ferreira, et al.
Publicado: (2016)